Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) received favorable written feedback from the U.S. Food and Drug Administration following a Type C meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The feedback covers the clinical pharmacology and non‑clinical development elements of the program and confirms alignment with the FDA on these key disciplines.
The FDA’s comments indicate that the company’s proposed clinical pharmacology strategy and non‑clinical data package meet the agency’s expectations, clearing a major regulatory hurdle that has historically delayed the initiation of pivotal trials for rare neurodegenerative indications.
"This meeting confirms alignment with the FDA in two key disciplines and represents an important step toward initiation of the Phase 3 program." – David Stamler, CEO.
Alterity will next seek agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End‑of‑Phase 2 meeting scheduled for mid‑2026. The company’s cash and cash equivalents stood at A$49.2 million as of December 31 2025, bolstered by a capital raise of approximately A$20 million in September 2025, providing a runway that covers planned expenditures for the next 12 months.
The positive feedback de‑risks the path to a pivotal trial, strengthens Alterity’s position in a disease area with no approved therapies, and could accelerate partnership discussions. However, the company still faces key uncertainties around FDA alignment on CMC and trial design, the translation of Phase 2 efficacy signals to a larger Phase 3 population, and the need to secure sufficient funding for the high‑cost pivotal study.
With the FDA’s current endorsement, Alterity is poised to finalize the CMC and trial design agreements and to hold the End‑of‑Phase 2 meeting in mid‑2026, after which the company will be positioned to launch the Phase 3 program if the agency’s remaining concerns are addressed.
Investors have responded positively to the announcement, reflecting confidence in the company’s regulatory progress and the potential for a first‑in‑class iron‑chaperone therapy to address an unmet medical need.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.